Mchardy
Alice Carolyn Mchardy, New York, NY US
Patent application number | Description | Published |
---|---|---|
20090093624 | Techniques for Linking Non-Coding and Gene-Coding Deoxyribonucleic Acid Sequences and Applications Thereof - Techniques for linking non-coding and gene coding regions of a genome are provided. In one aspect, a method of determining associations between non-coding sequences and gene coding sequences in a genome of an organism comprises the following steps. At least one conserved region is identified from one or more non-coding sequences. Additional instances of the conserved region are located in the untranslated or amino acid coding regions of one or more genes in the organism under consideration, and the conserved region is associated with the one or more biological processes in which these one or more genes participate. | 04-09-2009 |
20110178283 | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes - Sequences that can be used in the context of controlled gene regulation are provided. In one aspect, at least one sequence comprising at least one of one or more sequences having SEQ ID NO: 1 through SEQ ID NO: 747,326 is provided. One or more of the provided sequences may be computationally predicted, e.g., from publicly available genomes, using a method based on pattern discovery. In another aspect, a method for regulating the expression of a transcript comprises the step of said transcript containing a region that corresponds to at least one of the provided sequences having SEQ ID NO: 1 through SEQ ID NO: 747,326, the region being targeted either by a naturally occurring, or appropriately designed, interfering RNA molecule that regulates the expression of said transcript through post-transcriptional silencing. In a third aspect, a method for regulating the expression of a transcript comprises the step of at least one of the provided sequences having SEQ ID NO: 1 through SEQ ID NO: 747,326 being used to design an interfering RNA molecule that contains a region that corresponds to the reverse complement of one or more of the one or more sequences having SEQ ID NO: 1 through SEQ ID NO: 747,326, the interfering molecule regulating, through post-transcriptional silencing, one or more transcripts that contain said sequence of the one or more sequences having SEQ ID NO: 1 through SEQ ID NO: 747,326, or a substantial fraction thereof. | 07-21-2011 |
Alice Carolyn Mchardy, Düsseldorf DE
Patent application number | Description | Published |
---|---|---|
20110280907 | METHOD AND SYSTEM FOR BUILDING A PHYLOGENY FROM GENETIC SEQUENCES AND USING THE SAME FOR RECOMMENDATION OF VACCINE STRAIN CANDIDATES FOR THE INFLUENZA VIRUS - A computer-implemented method and a computer system for identifying a phylogenetic tree from a plurality of biological sequences is provided. Each biological sequence is associated with a sampling date. First, the plurality of biological sequences is aligned and a distance matrix is obtained. Then, a subset of these sequences without any duplicated sequences is selected and a directed graph representation of the subset of biological sequences is generated based the associated sampling dates. Then, a minimum spanning tree is computed from the weighted directed graph representation. Then, in an iterative procedure, the sequences of unsampled evolutionary intermediates are inferred from mutation patterns that reflect the difference in sequence between the nodes in the minimum spanning tree. The new sequences are added with associated time stamps to the sequence set. Then, sets of identical sequences are removed. Then, an optimum branching is recomputed. This step is repeated until no new intermediates are found. In the final step, the sequences that have been set aside in the initializing step are added to the plurality of sequences derived in the update step. From this plurality of sequences an optimum branching is computed and identified as the phylogenetic tree. Amino acid changes repeatedly occurring on the internal branches of the obtained tree can be used to identify sequences and associated viral isolates suitable as vaccine strains for the following influenza season. | 11-17-2011 |
Colin Mchardy, Aberdeen GB
Patent application number | Description | Published |
---|---|---|
20100236792 | EXPANDING MULTIPLE TUBULAR PORTIONS - Apparatus for expanding first and second portions of a downhole tubular in a single trip comprises a support and first and second expansion devices. The first expansion device is mounted on the support and is operable to expand a first portion of tubular. The second expansion device is mounted to a second portion of tubular and is adapted to be engaged by the support following the expansion of the first portion of tubular, and is then used to expand the second portion of tubular. | 09-23-2010 |
Colin Mchardy, Balmedie GB
Patent application number | Description | Published |
---|---|---|
20100005643 | TUBING CONNECTION ARRANGEMENT - A tubing connection arrangement and a method used for coupling expandable tubing sections together. In one embodiment, there is disclosed a tubing connection arrangement comprising a first expandable tubing section defining a male portion; a second expandable tubing section defining a female portion, the first and second expandable tubing sections being engageable with one another; one of the first and second expandable tubing sections including a restraining member for restraining part of the other expandable tubing section; and the first expandable tubing section including a tapered shoulder for co-operating with a corresponding tapered shoulder of the second expandable tubing section. | 01-14-2010 |
Geoffrey Mchardy, Carp CA
Patent application number | Description | Published |
---|---|---|
20130322241 | TABLE-BASED LINK ADAPTATION FOR WIRELESS COMMUNICATION NETWORK TRANSMISSIONS - A method for link adaptation is provided. Data associated with a user device is stored. A first number of scheduling blocks, SBs, required to transmit the stored data is estimated based at least in part on a first modulation and coding scheme (MCS). The first MCS corresponds to a first channel performance level. A second MCS is determined based at least in part on a link quality. The second MCS corresponds to a second channel performance level. A determination is made whether second channel performance level is less than the first channel performance level. An operating MCS is selected based at least in part on whether second channel performance level is less than the first channel performance level. The data is scheduled for transmission based at least in part on the selected operating MCS. | 12-05-2013 |
20140177534 | Communication Protocol for Short Data Transmissions - A lightweight communication protocol reduces overhead for small data transmissions from a wireless device to a base station over an uplink channel. The wireless device is preconfigured with a device identifier that is known to the base station. The preconfigured device identifier is associated with a static tunnel between the base station and a serving gateway. The wireless device transmits application data to the base station in a medium access control packet without using higher layer protocols. When the base station receives the medium access control packet, it maps the application data to the tunnel associated with the preconfigured device identifier. | 06-26-2014 |
Ian H. Mchardy, Venice, CA US
Patent application number | Description | Published |
---|---|---|
20110207657 | Selectively Targeted Antimicrobial Peptides and the Use Thereof - The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., | 08-25-2011 |
20140155317 | SELECTIVELY TARGETED ANTIMICROBIAL PEPTIDES AND THE USE THEREOF - The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., | 06-05-2014 |
Ian Roger Mchardy, Waterloo CA
Patent application number | Description | Published |
---|---|---|
20160080217 | Methods and Systems for Auto-Starting and Auto-Stopping Databases - Systems and methods are presented for auto-starting and auto-stopping databases in a cloud server environment. In some embodiments, a method can include accessing, by an initial server in a network-based system, a request to connect to a target database located in a target server of the network-based system. The method can also include determining, by an administrative database (admin database) residing in the initial server, a location of the target database residing in the target server, switching an execution context from no database in the target server to a copy of the admin database in the target server, performing an auto-start procedure to auto-start the target database in the target server, switching the execution context from the admin database in the target server to the target database in the target server, and transmitting a completion acknowledgement indicating the target server is connected to the target DB. | 03-17-2016 |
John Mchardy, Oxnard, CA US
Patent application number | Description | Published |
---|---|---|
20120084032 | IDENTIFYING AND AMERLIORATING A DETERIORATING CONDITION FOR BATTERY NETWORKS IN-SITU - A temperature is measured for each terminal of the battery unit. The magnitude and sign of a temperature differential is calculated from the temperatures. The temperature differential is then correlated to a deteriorating condition of the battery unit. | 04-05-2012 |
20120105066 | SELF-CORRECTING AMPLIFIER SYSTEM - DC offsets introduced in battery testing equipment are automatically compensated for using complementary current-mode servo feedback. An op amp receives and amplifies a response signal, while also introducing internal errors manifested in the amplified response signal. A correction circuitry coupled to receive the amplified response signal and comprising a balanced circuit with a positive input correction device and a negative input correction device to remove the DC bias. The correction circuitry further comprises an error sensing device to correct for the internal errors introduced by the op amp. | 05-03-2012 |
20120123712 | DETERMINING REMAINING LIFE FRACTION FOR BATTERY NETWORKS IN-SITU - Determination of a remaining life fraction for a network of batteries during use in an electrical circuit is disclosed. A state of health of the battery network can be determined by measuring a change in impedance characteristics of the individual battery units and/or the battery network as a whole. More specifically, a mode and a severity of a failure can be determined for individual battery units. | 05-17-2012 |
Nicholas Mchardy, Baltyboys IE
Patent application number | Description | Published |
---|---|---|
20100099625 | Bio-security system - A method for preventing contamination of a teat during administration of a sealant comprises the steps of introducing/delivering a sterilising agent into the teat and subsequently delivering the sealant into the teat. A sealant injector | 04-22-2010 |
Nicholas Mchardy, County Wicklow IE
Patent application number | Description | Published |
---|---|---|
20110022000 | METHOD AND DEVICE - The invention relates to a method and device for treating or preventing or suppressing a disease or condition in a non-human animal. The method comprises the steps of providing a single delivery device containing two components for sequential delivery from the delivery device. A first component is delivered from the single delivery device into a teat canal of a non-human animal and subsequently the second component is delivered from the single delivery device into the teat canal. The components are delivered without substantial mixing of the components. | 01-27-2011 |
20130116657 | METHOD AND DEVICE - The invention relates to a method and device for treating or preventing or suppressing a disease or condition in a non-human animal. The method comprises the steps of providing a single delivery device containing two components for sequential delivery from the delivery device. A first component is delivered from the single delivery device into a teat canal of a non-human animal and subsequently the second component is delivered from the single delivery device into the teat canal. The components are delivered without substantial mixing of the components. | 05-09-2013 |
Stanton F. Mchardy, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20130035351 | Oximes For Treatment Of Peripheral And Central Nervous System Exposure To Acetyl Cholinesterase Inhibitors - The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates. | 02-07-2013 |
20140066421 | OXIMES FOR TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM EXPOSURE TO ACETYL CHOLINESTERASE INHIBITORS - The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates. | 03-06-2014 |
Stanton F. Mchardy, Conventry, RI US
Patent application number | Description | Published |
---|---|---|
20100324020 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors - The present invention relates to a series of substituted bicyclic[3.1.0]heteroaryl amides of the Formula I, wherein A, Q, X, Y, Z and R | 12-23-2010 |
Stanton Furst Mchardy, Helotes, TX US
Patent application number | Description | Published |
---|---|---|
20090163482 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR - This invention is directed to a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of formula (I) a process of en preparation of a compound of formula (I), a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above. | 06-25-2009 |
20100035873 | Diaryl Compounds and Uses Thereof - The invention relates to derivatives of a compound of formula I: | 02-11-2010 |
20100285087 | SINGLE PHENOTHIAZINE ENANTIOMERS AS AGENTS FOR THE PREVENTION OF BONE LOSS - Enantomerically purified phenothiazines are provided as active ingredients of medicaments to limit activity of bone resorbing cells so as to reduce bone loss. Novel phenothiazine derivatives are provided. A method of synthesizing enantiomerically pure phenothiazine derivatives is provided that avoids post-synthetic enantiomeric resolution. | 11-11-2010 |
Tatiana Faria Da Fonseca Mchardy, Sutton GB
Patent application number | Description | Published |
---|---|---|
20150126471 | 5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-PYRIDYL]AMINO]PY- RAZINE-2-CARBONITRILE AND THERAPEUTIC USES THEREOF - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme. | 05-07-2015 |